Your search history is turned on.
Date: June 4, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - Aurora - CanniMed- Notice of Change in Corporate Structure _2_.doc NOTICE OF CHANGE IN CORPORATE STRUCTURE Pursuant to Section 4.9 of National Instrument 51-102 This notice is provided pursuant to the requirements of Section 4.9 of National Instrument 51- 102 Continuous Disclosure Obligations. Item 1. Names of the Parties to the Tran...
Date: April 16, 2018 Jurisdictions: All jurisdictions
Aurora Cannabis Gains Exclusive License to Novel Patented Sub-Lingual Wafer Technology from CTT Pharmaceutical Aurora Cannabis Gains Exclusive License to Novel Patented Sub-Lingual Wafer Technology from CTT Pharmaceutical Convenient, High Bioavailability, Rapid Onset of Action Drug Delivery TSX: ACB TSX: CMED OTC: CTTH EDMONTON, SASKATOON and HAMILTON, ON, April 16, 2018 /CNW/ - Aurora C...
Date: April 13, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
NOTICE OF COMPULSORY ACQUISITION by AURORA CANNABIS INC. of common shares of CANNIMED THERAPEUTICS INC. April 9, 2018 This Notice has been sent to you as one of the common shareholders of CanniMed Therapeutics Inc. (CanniMed) who did not accept the offer dated November 24, 2017 (the Original Offer), as amended by the notice...
Date: April 13, 2018 Jurisdictions: All jurisdictions
Aurora Cannabis Commences Compulsory Acquisition of Remaining CanniMed Shares Aurora Cannabis Commences Compulsory Acquisition of Remaining CanniMed Shares TSX: ACB TSX: CMED EDMONTON, April 13, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced today that the Company has exercised its right under the compulsory acquisition provisions in...
Date: April 11, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - TOR01-#7353258-v2-CanniMed_-_Material_Change_Report_-_B_Zettl_resignation_and_A_Jerome_interim_CEO.docx 1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company CanniMed Therapeutics Inc. (CanniMed or the Company) #1 Plant Technology Road Saskatoon, Saskatchewan S7K 3J8 Item 2: Date of Material Change April 2, 2018. ...
Date: April 4, 2018 Jurisdictions: All jurisdictions
CanniMed Signs Letter of Intent with Pharmasave CanniMed Signs Letter of Intent with Pharmasave TSX: ACB TSX: CMED EDMONTON and SASKATOON, April 4, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CanniMed Therapeutics Inc. ("CanniMed") (TSX: CMED) announced today that CanniMed has entered into a Letter of Intent to become a preferred suppli...
Date: April 2, 2018 Jurisdictions: All jurisdictions
Andr Jrme Appointed Interim CEO of CanniMed Andr Jrme Appointed Interim CEO of CanniMed Resigning CEO Brent Zettl to Provide Advisory Services TSX: ACB TSX: CMED EDMONTON and SASKATOON, April 2, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CanniMed Therapeutics Inc. ("CanniMed") (TSX: CMED) announced today that Mr. Brent Zettl h...
Date: March 26, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - TOR01-#7329841-v3-CanniMed_-_Material_Change_Report_-_Board_Changes.docx 1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company CanniMed Therapeutics Inc. (CanniMed or the Company) #1 Plant Technology Road Saskatoon, Saskatchewan S7K 3J8 Item 2: Date of Material Change March 15, 2018. Item 3: News Release The n...
Date: March 19, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Saskatchewan
Microsoft Word - Form 52-109F2 Certification of Interim Filings - CanniMed Therapeutics - CFO - Q1 2018.docx Form 52-109F2 Certification of Interim Filings I, John Knowles, Chief Financial Officer of CanniMed Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the interim filing...
Microsoft Word - Form 52-109F2 Certification of Interim Filings - CanniMed Therapeutics - CEO - Q1 2018.docx Form 52-109F2 Certification of Interim Filings I, Brent Zettl, President and Chief Executive Officer of CanniMed Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A (together, the inter...